Centogene N.V. (CNTG)
| Market Cap | 13.62M |
| Revenue (ttm) | 55.72M |
| Net Income (ttm) | -62.11M |
| Shares Out | 27.87M |
| EPS (ttm) | -1.55 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,870 |
| Open | 0.490 |
| Previous Close | 0.480 |
| Day's Range | 0.450 - 0.490 |
| 52-Week Range | 0.431 - 1.980 |
| Beta | -0.81 |
| Analysts | Strong Buy |
| Price Target | 1.50 (+206.19%) |
| Earnings Date | Sep 7, 2023 |
About CNTG
Centogene N.V., together with its subsidiaries, engages in the research and development of products for human genetics in Europe, the Middle East, North America, Latin America, and the Asia Pacific. It provides data-driven answers to patients, physicians, and pharmaceutical companies for rare and neurodegenerative diseases. It operates through two segments: Pharmaceutical and Diagnostics. The company provides target and drug screening, clinical development, market access and expansion, as well as CENTOGENE Biodatabank licenses and insight repor... [Read more]
Financial Performance
In 2022, Centogene's revenue was 47.47 million, an increase of 12.40% compared to the previous year's 42.23 million. Losses were -31.92 million, -30.31% less than in 2021.
Financial numbers in EUR Financial StatementsAnalyst Forecast
According to one analyst, the rating for CNTG stock is "Strong Buy" and the 12-month stock price forecast is $1.5.
News
CENTOGENE Receives Nasdaq Non-Compliance Notice
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, April 02, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (“Centogene”, “we”, or the “Company”), the essential life science partner for data-dr...
CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 19, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenera...
CENTOGENE Collaborates on Research Published in Science Showing Immunopathological Landscape of Human Pre-TCRα Deficiency
Complete Pre-TCRα Deficiency Found to be Very Rare, Partial Form More Common Than Expected Complete Pre-TCRα Deficiency Found to be Very Rare, Partial Form More Common Than Expected
CENTOGENE Explores Strategic Alternatives
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (the “Company”), the essential life science partner for data-driven answers in rare an...
CENTOGENE Announces Receipt of Nasdaq Notice of Delisting and Intention to Request a Hearing
Notice of Delisting Will Not Immediately Result in the Suspension or Delisting of the Company's Securities Notice of Delisting Will Not Immediately Result in the Suspension or Delisting of the Company...
CENTOGENE and the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine Announce Rare Disease Research Collaboration
Aims to Leverage Diversified Data to Accelerate and De-Risk Drug Discovery and Clinical Development Aims to Leverage Diversified Data to Accelerate and De-Risk Drug Discovery and Clinical Development
CENTOGENE Receives French Research Tax Credit Accreditation
CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Centogene N.V.
CENTOGENE Announces Preliminary Full Year 2023 Revenue
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerat...
CENTOGENE Announces Voting Results of Extraordinary General Meeting
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerat...
CENTOGENE's Frontotemporal Dementia (FTD) Genetic Study, EFRONT, Reaches Initial Patient Enrollment Milestone
CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenera...
CENTOGENE and Lifera, a Public Investment Fund (PIF) Company, Complete Strategic Joint Venture Transaction
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerat...
CENTOGENE, University College London, and Global Team of Researchers Discover Gene Associated With New Neurodevelopmental Disease Linked to Early-Onset Dystonia and Parkinsonism
Collaborative research initiative leveraged CENTOGENE's Whole Exome Sequencing (WES) to reveal disease-causing gene called ACBD6 (Acyl-CoA Binding Domain Containing 6) Over seven years, a total of 45 ...
CENTOGENE Expands Multiomic Diagnostic Portfolio With Newly-Launched Transcriptomic Offering
Incorporating RNA sequencing provides better diagnostics to enable a more complete understanding of disease biology Incorporating RNA sequencing provides better diagnostics to enable a more complete u...
CENTOGENE to Present at H.C. Wainwright 25th Annual Global Investment Conference
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenera...
CENTOGENE Reports First Half 2023 Financial Results
Strong Revenues and Steady Growth in Both Diagnostics and Pharma Segments Drive Sustainable Financial Performance Strong Revenues and Steady Growth in Both Diagnostics and Pharma Segments Drive Sustai...
Centogene shares climb after study confirms biomarker for Gaucher disease
Shares of Centogene NV CNTG, +8.31% gained 7% premarket on Friday after the company announced data confirming the utility of its proprietary biomarker lyso-Gb1 in indicating the severity of Gaucher di...
CENTOGENE Announces Publication Establishing Lyso-Gb1 as a Predictive Biomarker for Gaucher Disease Patients
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 01, 2023 (GLOBE NEWSWIRE) -- CENTOGENE N.V. (Nasdaq: CNTG) (the “Company”), the essential life science partner for data-driven answers in rare a...
CENTOGENE Receives Nasdaq Non-Compliance Notification Regarding Minimum Market Value of Publicly Held Shares Deficiency
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (“we” or the “Company”), the essential life science partner for data-driven answers in...
CENTOGENE to Participate in Upcoming Conferences in August
CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenera...
CENTOGENE Regains Compliance With Nasdaq Listing Requirements
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 14, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (the “Company”), the essential life science partner for data-driven answers in rare an...
CENTOGENE Biodatabank Reveals Unique Genetic Variants in World's Largest Niemann-Pick Type C1 Disease Cohort
Results Published in European Journal of Human Genetics Demonstrate Unprecedented Insights to Accelerate Potential Treatment Options Results Published in European Journal of Human Genetics Demonstrate...
Lifera and CENTOGENE, Enter Strategic Collaboration - Forming Saudi Arabian Joint Venture to Increase Access to Leading Data-Driven Multiomic Testing
Joint Venture (JV) combines CENTOGENE's global leadership in multiomics with local insight of Lifera, a biopharmaceutical company wholly owned by the Public Investment Fund (PIF) based in Riyadh. JV f...
CENTOGENE Announces Approval of All Resolutions Tabled at 2023 Annual General Meeting
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 30, 2023 (GLOBE NEWSWIRE) -- CENTOGENE N.V. (Nasdaq: CNTG) (the “Company”), the essential life science partner for data-driven answers in rare an...
Centogene shares jump on joint venture with Lifera
Shares of Centogene NV CNTG, -2.20%, which specializes in genetic diagnostics for rare diseases, jumped 50% in premarket trading Tuesday after the company announced a joint venture with Lifera, a biop...
CENTOGENE and Lifera, a Biopharma Company Owned by the PIF, Enter Strategic Collaboration – Forming Saudi Arabian Joint Venture to Increase Access to Leading Data-Driven Multiomic Testing and Securing CENTOGENE $30 Million Investment
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN and RIYADH, Saudi Arabia, June 27, 2023 (GLOBE NEWSWIRE) -- CENTOGENE N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers i...